Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros Grivas from Fred Hutchinson Cancer Center and Dr. Sumanta (Monty) Pal from City of Hope.

---

CHECK OUT OUR SPONSOR

Siemens Healthineers Theranostics

https://www.siemens-healthineers.com/en-us/clinical-specialities/theranostics

---

SYNPOSIS

The conversation initially focuses on advanced urothelial carcinoma and the EV302 trial, discussing detailed insights from the quality-of-life results presented at ASCO. The experts offer relevant clinical perspectives for modern metastatic urothelial carcinoma management, focusing on pembrolizumab plus enfortumab vedotin. Further, they delve into breaking biomarker research at ASCO, including KIM-1 in adjuvant renal cell carcinoma (RCC) therapy and the HIF-2 inhibitor DFF332 for chromophobe RCC.

---

TIMESTAMPS

00:00 - Introduction

03:42 - Pembrolizumab and Enfortumab Vedotin Trial Insights

07:43 - Future Trials and Treatment Strategies

21:27 - Javelin Bladder 100 Trial Discussion

32:05 - Growth Factor Use

36:21 - Future Directions of Biomarkers

38:55 - Kidney Cancer Biomarker Trials

53:40 - Concluding Thoughts